Bacillus Calmette-Guérin (BCG), an attenuated vaccine strain derived from virulent *Mycobacterium bovis*, has been in use as a vaccine against tuberculosis for nearly a century \[[@JIU347C1]\]. Vaccination in early childhood induces an immune response to *Mycobacterium tuberculosis*, which prevents disseminated miliary and meningeal forms of the disease. However, protection against the common pulmonary tuberculosis that affects people of all age groups is insufficient \[[@JIU347C2]\]. Thus, there is an urgent need for novel vaccines that (1) induce efficacious protection against tuberculosis and (2) are also safe in human immunodeficiency virus (HIV)^+^ individuals, in whom an otherwise harmless live vaccine can cause disseminated disease \[[@JIU347C3], [@JIU347C4]\].

Early animal studies of BCG identified CD4^+^ T cells as key elements underlying immunological memory against subsequent challenge with *M. tuberculosis* \[[@JIU347C5], [@JIU347C6]\]. Adoptively transferred transgenic CD4^+^ T cells specific for antigen (Ag) 85B (Ag85B; Rv1886c), also expressed by BCG, are capable of controlling a chronic bacterial load in *M. tuberculosis*--infected lungs \[[@JIU347C7], [@JIU347C8]\]. CD4^+^ T cells are a heterogeneous population composed of effector and memory (T~M~) subtypes coexpressing a variety of cytokines, chemokines, and receptors with varying impact on protective immunity \[[@JIU347C9], [@JIU347C10]\]. The early appearance of T-helper 1 (Th1) type CD4 effector memory T cells (T~EM~) secreting interferon γ (IFN-γ)/tumor necrosis factor α (TNF-α) has been considered crucial for orchestration of protective immunity in the infected lung, but recently, it has been questioned whether expression of these proinflammatory mediators in the lung is indeed sufficient for control of tuberculosis \[[@JIU347C11], [@JIU347C12]\]. Systemic maintenance of T~M~ following vaccination and their recruitment to the lung following infection remains a key focus of vaccine and biomarker studies \[[@JIU347C13], [@JIU347C14]\].

The tuberculosis vaccine candidate containing recombinant BCG *Δure*C::*hly* (rBCG; VPM1002), which secretes pore-forming listeriolysin (hly), has proven its clinical safety and immunogenicity \[[@JIU347C15], [@JIU347C16]\]. Here, we pursue an in-depth analysis of the endogenous mycobacteria-specific T~M~, comparing the more efficacious rBCG with canonical BCG to determine which T~M~ responses are prerequisites for superior protection against tuberculosis. It remains challenging to effectively analyze the kinetics and components of the spatially diffuse immune response in humans or animal models induced by BCG, as live bacteria can disseminate to disparate organs in different individuals. We harnessed a sensitive technique in which peptide major histocompatibility complex (MHC) class II tetramer^+^ T cells were enriched from pooled secondary lymphoid organs of vaccinated mice. This approach allowed us to precisely quantify the kinetics of specific CD4^+^ T cells following vaccination and subsequent *M. tuberculosis* aerosol challenge and to identify specific central memory T cells (T~CM~) as mediators against pulmonary tuberculosis.

MATERIALS AND METHODS {#s2}
=====================

*M. tuberculosis* and BCG Culture {#s2a}
---------------------------------

BCG SSI 1331 (American Type Culture Collection \[ATCC\]; no. 35733), rBCG, and *M. tuberculosis* H37Rv (ATCC; no. 27294) were prepared as described previously \[[@JIU347C17]\]. For colony-forming unit (CFU) enumeration, serial dilutions were performed in phosphate-buffered saline containing 0.05% Tween 80 and plated onto Middlebrook 7H11 agar. Plates were incubated at 37°C for 3--4 weeks prior to counting.

Animals and Infections {#s2b}
----------------------

All experimental procedures involving mice were performed in accordance with requirements of and approval by the State Office for Health and Social Services (Landesamt für Gesundheit und Soziales), Berlin, Germany. C57BL/6 mice were purchased from Charles River Laboratories (Germany), and P25 Tg \[[@JIU347C7]\] and B6PL lines from Jackson Laboratories (USA) were bred in house. Mice were 8--12 weeks old, matched for age and sex, and kept under specific pathogen-free conditions. Vaccines (0.5--1.0 × 10^6^ CFU BCG or rBCG in 100 ul phosphate buffered saline) were delivered subcutaneously at the tail base. A Glas-Col inhalation exposure system was used for aerosol infection of mice with low-dose (150--200 CFU) *M. tuberculosis*, confirmed by plating lung homogenates 1 day after infection.

Tetramer-Based Cell Enrichment and Flow Cytometry {#s2c}
-------------------------------------------------

I-Ab:Ag85B (280--294: FQDAYNAAGGHNAVF) tetramers were provided by the National Institutes of Health (NIH) tetramer facility (USA), I-Ab:ESAT-6 (1--20: MTEQQWNFAGIEAAASAIQG) tetramers were made in house. A total of 10 nM of Ag85B tetramer was added to single-cell suspensions of pooled spleen and lymph nodes (LNs; cervical, retromaxillary, inguinal, peripheral, and mesenteric) or lung cells for 1 hour at room temperature. For memory phenotyping, 2 µg of CXCR5 (2G8; Becton Dickinson) and CCR7 (5B12 RUO) antibodies (Ab) were included. Tetramer^+^ cells were enriched according to a published protocol \[[@JIU347C18]\]. In brief, samples were incubated with magnetic antifluorochrome microbeads and run through an LS column (Miltenyi Biotec), and the resulting cell fractions were analyzed by flow cytometry. All Ab were from eBioscience, unless otherwise noted. For identification of surface markers, the sample was stained on ice with Ab specific for B220 (RA3-6B2), CD11b (MI-70), CD11c (N418), CD8α (5H10; Invitrogen, Carlsbad, CA), PD-1 (J43), CD4 (RM4-5), CD3ε (145-2C11), CD44 (IM7), CD90.1 (HIS51), and/or CD90.2 (53-2.1). Intracellular staining with Ab for Foxp3 (FJL-16s), RORγt (B2D), T-bet (ebio4B10), and Bcl-6 (7D1, Santa Cruz) was performed with Foxp3 fixation/permeabilization buffers (eBioscience) in accordance with the manufacturer\'s instructions. Analysis was performed on an LSR II or FACS Canto II (Becton Dickinson) flow cytometer. Data were analyzed with FlowJo (TreeStar).

Isolation of Lung-Resident Lymphocytes {#s2d}
--------------------------------------

Lungs were harvested from perfused animals and digested with collagenase (0.7 mg/mL Collagenase IV \[Sigma-Aldrich\] and 0.3 mg/mL Collagenase D \[Roche\]) in complete Roswell Park Memorial Institute (RPMI) 1640 medium complemented with 10 µg/mL brefeldin A (Santa Cruz) at 37°C in 5% CO~2~ for 30 minutes. Single-cell suspensions were prepared by mechanical dissociation through a 70-µm nylon mesh in RPMI 1640 medium (with 10% fetal calf serum \[Gibco\], penicillin/streptomycin, and brefeldin A\].

Adoptive Cell Transfer {#s2e}
----------------------

Spleens and LNs were pooled from 10 rBCG-vaccinated donor mice at day 15, and APC-Ag85B:I-Ab CD4^+^ T cells were enriched with anti-APC beads over a magnetic column (Miltenyi Biotec) prior to cell sorting using a FACS Aria II. Endogenous or P25 Ag85B-specific T~EM~, T~CM~, or T~FH~ at \>85% purity were injected intravenously into recipient mice. Naive Tg P25 cells were enriched from the pooled LNs from CD90.1^+^ congenic mice, using a CD4^+^ T-cell isolation kit (Miltenyi Biotec).

Enzyme-Linked Immunosorbent Assay (ELISA) {#s2f}
-----------------------------------------

Multisorb ELISA plates (NUNC) were coated overnight with 2 μg/mL of protein lysate prepared by sonicating log-phase H37Rv *M. tuberculosis*. Nonspecific binding was blocked by preincubation for 2 hours with 3% bovine serum albumin (BSA). Serial dilutions were added to the plate prepared in 1% BSA in phosphate-buffered saline for 2 hours, followed by washing and detection of OD by use of alkaline phosphatase--conjugated isotype-specific secondary Ab (Southern Biotech).

Statistical Analysis {#s2g}
--------------------

GraphPad Prism software (USA) was used for statistical analysis. Bacterial titers were analyzed by the nonparametric Mann--Whitney test. Frequencies and numbers of specific cells were compared using a 2-way Student *t* test or 1-way analysis of variance, followed by the Bonferroni posttest.

RESULTS {#s3}
=======

Increased Ag-Specific CD4^+^ T-Cell Responses Induced by rBCG, Compared With Those Induced by Canonical BCG {#s3a}
-----------------------------------------------------------------------------------------------------------

rBCG provides superior protection against aerosol challenge with *M. tuberculosis* \[[@JIU347C16]\]. Moreover, rBCG has an improved safety profile, showing diminished persistence following subcutaneous vaccination of C57BL/6 mice (Figure [1](#JIU347F1){ref-type="fig"}) \[[@JIU347C15]\]. rBCG also disseminated rarely to peripheral lymphoid organs such as the spleen and never disseminated to the lung (Figure [1](#JIU347F1){ref-type="fig"}). BCG induces T~M~ responses to shared mycobacterial Ag, which can enhance and accelerate the immune response following subsequent challenge with *M. tuberculosis* \[[@JIU347C19]\]. To characterize CD4^+^ T-cell responses to rBCG, an MHC class II tetramer of Ag85B-derived peptide (Ag85B:I-Ab) was used to enrich the CD44^lo^ naive repetoire from untreated controls (mean cell count \[±standard error of the mean {SEM}\], 87 ± 21 cells), and the expanded population from vaccinated animals (Figure [2](#JIU347F2){ref-type="fig"}*A*). rBCG drove superior expansion, which persisted 3 months after clearance of the vaccine and contraction of the immune response (mean cell count \[±SEM\], 662 ± 190.8 cells in BCG recipients and 1625 ± 379.8 cells in rBCG recipients at day 84; n = 10; Figure [2](#JIU347F2){ref-type="fig"}*B*). The increased T-cell number was confirmed at the polyclonal level by measuring the proportion of CD4^+^ T cells that upregulated CD154 in an Ag-specific manner after stimulation with mycobacterial lysate ([Supplementary Figure 1](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiu347/-/DC1)) \[[@JIU347C20]\]. We conclude that rBCG induced a quantitative increase in CD4^+^ T cells specific for mycobacterial Ag. Figure 1.Kinetics of bacillus Calmette Guerin (BCG) and recombinant BCG (rBCG) clearance. Mice were vaccinated with either BCG or rBCG subcutaneously on day 0. Shown are mean colony-forming units (CFU; ± standard error of the mean) of 2 pooled experiments (n = 10). Figure 2.Kinetics of endogenous CD4^+^ T-cell responses in secondary lymphoid organs following BCG or rBCG vaccination. *A*, Flow cytometry of magnetic column--bound and unbound fractions following enrichment of Ag85B:I-Ab^+^ CD4^+^ T cells, gated on CD3^+^CD4^+^ T cells, from pooled lymph nodes and spleens obtained from individual naive controls or 14 days after vaccination, as described in Figure [1](#JIU347F1){ref-type="fig"}. *B*, Total numbers of Ag85B:I-Ab^+^ CD4^+^ T cells in pooled secondary lymphoid organs. Data are representative values (*A*) or pooled values from 3 independent experiments (*B*; n = 12). \**P* \< .05 and \*\**P* \< .01, by a 2-tailed Student *t* test.

Effector CD4^+^ T-Cell Migration to the Lung Following Vaccination Echoes Systemic Expansion {#s3b}
--------------------------------------------------------------------------------------------

The systemic dynamics of Ag-specific CD4^+^ T-cell responses were recapitulated in the peripheral target organ, the lung, where subcutaneous administration of rBCG at the tail base also induced increased numbers and proportions of Ag85B-specific CD4^+^ T cells, compared with BCG (Figure [3](#JIU347F3){ref-type="fig"}). Rare Ag-specific T cells could be detected above background without enrichment only at the peak of the response at 14 days after receipt of rBCG (Figure [3](#JIU347F3){ref-type="fig"}), suggesting that neither vaccine generated a pool of mucosa-resident T~EM~, perhaps surprisingly despite occasional dissemination following BCG but not rBCG vaccination (Figure [1](#JIU347F1){ref-type="fig"}). Thus, the T~M~ generated by subcutaneously administered BCG or rBCG are maintained over the long term in the secondary lymphoid organs, rather than in the lung. Figure 3.Antigen-specific CD4^+^ T cells migrate to the lung following subcutaneous BCG or rBCG vaccination. *A*, Numbers and frequencies of unenriched Ag85B:I-Ab^+^ CD4^+^ T cells in lung. *B*, Representative flow cytometry of the percentage of Ag85B:I-Ab^+^ CD4^+^ T cells in lung, gated on CD3^+^CD4^+^ T cells, 14 days after vaccination as described in Figure [1](#JIU347F1){ref-type="fig"}. Data are mean values (± standard error of the mean) of pooled samples (*A*) or representative values from individual mice from 2--3 experiments (*B*; n = 8--12). \**P* \< .05 and \*\*\**P* \< .001, by a 2-tailed Student *t* test.

rBCG Induces Elevated T~CM~ and Follicular Helper T-Cell (T~FH~) Differentiation of CD4^+^ T Cells {#s3c}
--------------------------------------------------------------------------------------------------

In addition to the quantitative increase in Ag-specific T cells in rBCG recipients, compared with BCG recipients, enriched Ag85B:I-Ab^+^ cells expressed different T~M~ lineage surface markers. While both vaccines generated similar numbers of T~EM~ (CCR7^--^CXCR5^--^PD-1^--^), rBCG increased the number of T~CM~ (CCR7^+^CXCR5^+^PD-1^+^) during the peak of the response (Figure [4](#JIU347F4){ref-type="fig"}*A*). As viable rBCG is quickly cleared in the first weeks following receipt in C57BL/6 mice, we suspected that persistence of Ag85B-specific T cells was due to the establishment of a pool of T~EM~ and T~CM~, rather than to T~H~ maintained by the presence of live bacteria, but discriminating between the T~EM~ and T~CM~ phenotypes from effector Th1 and T~FH~ responses is challenging by means of surface phenotype alone. Numerical increase of specific T~FH~ following rBCG vaccination was identified on the basis of their very high expression of the surface markers, CXCR5 and PD-1 (CCR7^+^CXCR5^hi^PD-1^hi^), and the increased intracellular abundance of the germinal center--associated transcription factor Bcl-6 \[[@JIU347C21]\], compared with other T~M~ subsets (Figure [4](#JIU347F4){ref-type="fig"}*B* and 4*C*). However, Ag-specific T cells in rBCG recipients displayed a lower abundance of other indicators of effector phenotype differention, such as Th1 effector transcription factor T-bet that drives IFN-γ/TNF-α secretion (Figure [4](#JIU347F4){ref-type="fig"}*C*) \[[@JIU347C22]\]. Furthermore, cytokine secretion was only rarely detected in Ag-specific CD4^+^ T cells isolated ex vivo from BCG recipients, even at the peak of the response, as has been previously shown for Ag-specific T cells following *M. tuberculosis* infection (data not shown) \[[@JIU347C23]\]. Specific CD4^+^ T-cell expression of T regulatory, T~H17~, or T~FH~ transcription factors FoxP3, RORγt, or Bcl-6 \[[@JIU347C24]\], respectively, was negligible following both vaccination regimens, supporting the notion that these cells reflected a memory rather than an effector phenotype (Figure [4](#JIU347F4){ref-type="fig"}*C*). After 3 months, specific CD4^+^ T cells enriched from secondary lymphoid organs from BCG or rBCG recipients exhibited distinct ratios of memory subsets: rBCG drove greater expansion and persistence of T~CM~ (Figure [4](#JIU347F4){ref-type="fig"}*C* and 4*D*). The T~FH~ population was also increased following rBCG but not BCG receipt but gradually contracted to preimmunization levels by day 90 and was thus unlikely to play a role in recall responses in this model (Figure [4](#JIU347F4){ref-type="fig"}*C* and 4*D*). The expanded Ag-specific T~CM~ population after rBCG vaccination was thus a potential correlate of protection against pulmonary tuberculosis. Figure 4.Vaccination with rBCG expands the central memory compartment of antigen (Ag)--specific CD4^+^ T cells. *A--C*, Data from pooled lymphoid organs from individual mice at day 14 after receipt of BCG or rBCG. *A*, Representative flow cytometry results showing memory markers gated on CD3^+^CD4^+^Ag85B:I-Ab^+^ T cells enriched from vaccinated or naive control mice. *B*, Surface CCR7 or nuclear Bcl-6 expression on representative naive CD3^+^CD4^+^Ag85B:I-Ab^+^ populations or CCR7^--^CXCR5^--^PD1^--^ (T~EM~), CCR7^+^CXCR5^+^PD1^--^ (T~CM~), and CCR7^+^CXCR5^hi^PD1^hi^ (T~FH~) populations from rBCG recipients. *C*, Intracellular expression of transcription factors by CD3^+^CD4^+^Ag85B:I-Ab^+^ in naive mice, BCG recipients, or rBCG recipients. *D*, Mean total numbers (± standard error of the mean) of CD3^+^CD4^+^Ag85B:I-Ab^+^ T~EM~, T~CM~, and T~FH~ gated as in panel *B* and enriched from pooled lymphoid organs from individual animals following vaccination. *E*, Mean frequency of effector populations among Ag85B:I-Ab^+^ CD4^+^ T cells gated as in panel *B*, 90 days after vaccination. Data are representative values from 3 independent experiments (*A*--*C*) or pooled values from 2--3 experiments (*D* and *E*; n = 6--10). \**P* \< .05, \*\**P* \< .01, and \*\*\**P* \< .001, by a 2-tailed Student *t* test.

rBCG Induces Enhanced Ab Production to Mycobacterial Ag {#s3d}
-------------------------------------------------------

The T~FH~ population stimulates germinal center B-cell responses \[[@JIU347C25]\], but the role of B cells and Ab in tuberculosis remains incompletely understood \[[@JIU347C26], [@JIU347C27]\]. We therefore verified the functionality of the increased Ag-specific T~FH~ population following rBCG receipt by examining sera obtained from vaccinated mice for Ab, using an *M. tuberculosis* protein lysate ELISA. We observed significantly higher serum reactivity in rBCG recipients, compared with BCG recipients, by 1 month after vaccination, which persisted as long as 3 months later (Figure [5](#JIU347F5){ref-type="fig"}*A*). This response was dominated by class switch to the immunoglobulin (Ig) G2c and IgG2b isotypes, although the IgG1 level was also increased to some extent (Figure [5](#JIU347F5){ref-type="fig"}*A* and [Supplementary Figure 2](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiu347/-/DC1)). In contrast, Ig M levels were similar in all groups, and specific Ig A was not detected ([Supplementary Figure 2](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiu347/-/DC1) and data not shown). Therefore, rBCG induced Ab with high efficacy. Intriguingly, preexisting specific Ab induced by rBCG persisted after aerosol challenge with *M. tuberculosis* 3 months after vaccination, and levels remained markedly higher 28 days following infection, compared with levels in both untreated mice and BCG recipients (Figure [5](#JIU347F5){ref-type="fig"}*B*). To determine whether increased mycobacteria-specific Ab was protective, we passively transferred serum from BCG recipients and rBCG recipients into naive animals but did not detect impact on tuberculosis ([Supplementary Figure 2](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiu347/-/DC1)). Figure 5.Vaccination with rBCG induces increased production of *Mycobacterium tuberculosis*--reactive antibody, compared with BCG. Mice were vaccinated with BCG or rBCG and were challenged 3 months later with a low dose of *M. tuberculosis*, alongside naive controls. The OD of *M. tuberculosis*--reactive immunoglobulin G2c (IgG2c) in sera, measured by enzyme-linked immunosorbent assay, in BCG and rBCG recipients (*A*) or in naive mice, *M. tuberculosis* recipients, BCG plus *M. tuberculosis* recipients, and rBCG plus *M. tuberculosis* recipients. Data show mean pooled values (± standard error of the mean) from 2 experiments (n = 10). \*\**P* \< .01\*\*\**P* \< .001, and \*\*\*\**P* \< .0001, by 1-tailed analysis of variance, followed by the Bonferroni posttest.

rBCG Provides Improved Protection Against Pulmonary Tuberculosis {#s3e}
----------------------------------------------------------------

We interrogated whether the enhanced T~CM~ persistence after rBCG receipt correlated with improved T-cell recruitment to the lung after challenge with *M. tuberculosis*. To this end, we challenged vaccinated mice with a low dose of aerosolized *M. tuberculosis* 3 months after vaccination. As shown previously for BALB/c mice, rBCG-recipient C57BL/6 mice showed superior protection in the lung over BCG recipients, particularly late in infection (Figure [6](#JIU347F6){ref-type="fig"}*A*) \[[@JIU347C15], [@JIU347C28]\], but dissemination of *M. tuberculosis* to the spleen and liver was similar ([Supplementary Figure 3](http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jiu347/-/DC1)). T~M~ are thought to rapidly expand in the LNs and subsequently migrate to the lung before their naive counterparts when reexposed to Ag. To determine whether T~M~ recall responses to Ag85B were increased in the lung, cell isolation was performed on day 14, the earliest time point at which T cells are recruited to the periphery in murine tuberculosis, where they provide a brake on bacterial growth and lung pathology \[[@JIU347C29]\]. We did not detect significantly increased Ag85B-specific CD4^+^ T-cell recruitment to the spleen or lung at day 14 in vaccinated or unvaccinated mice (Figure [6](#JIU347F6){ref-type="fig"}*B*). We also quantified the primary CD4^+^ T-cell response to *M. tuberculosis* early secreted Ag-6 (ESAT-6; Rv3875), which is not expressed by BCG, as well as total CD4^+^ T-cell numbers in the lung. Again, the number of primary CD4^+^ T cells specific to ESAT-6 were similar between all groups at day 14 following *M. tuberculosis* infection (Figure [6](#JIU347F6){ref-type="fig"}*B*). Thus, quantitative differences in Ag-specific T-cell responses did not underlie the superior protection against tuberculosis induced by rBCG, compared with BCG. Figure 6.Vaccination with rBCG induces superior protection over BCG in the lung despite similar CD4^+^ T-cell recruitment at early time points after *Mycobacterium tuberculosis* infection. Mice were vaccinated and challenged with *M. tuberculosis* as described in Figure [5](#JIU347F5){ref-type="fig"}. *A*, *M. tuberculosis* colony-forming units (CFU) in lungs 30 and 60 days following *M. tuberculosis* challenge. *B* and *C*, Total numbers of memory Ag85B:I-Ab^+^ (*B*) and primary (*C*) ESAT6:I-Ab^+^ CD4^+^ T cells in lungs, quantified by flow cytometry, 14 days after *M. tuberculosis* infection. All graphs show mean ± standard error of the mean of pooled values from 2 experiments (n = 10). \*\**P* \< .01, \*\*\**P* \< .001, and \*\*\*\**P* \< .0001, by the Mann--Whitney *U* test.

Adoptive Transfer of T~CM~ Rather Than T~EM~ Protects Against Tuberculosis {#s3f}
--------------------------------------------------------------------------

To compare differential protection by endogenous Ag-specific T~M~ subsets, we designed an adoptive T-cell transfer system that removed confounding effects by Ab, memory and plasma B cells, CD8^+^ T cells, or other innate and adaptive components of memory that may arise after vaccination (Figure [7](#JIU347F7){ref-type="fig"}*A*) \[[@JIU347C29], [@JIU347C30]\]. Congenic mice expressing the discriminatory CD90.1 marker received rBCG, and the polyclonal Ag85B:I-Ab^+^ T-cell population was purified into either T~EM~ (8000 per recipient) or T~CM~/T~FH~ (2000 per recipient) by FACS before intravenous transfer to naive C57BL/6 recipients (Figure [7](#JIU347F7){ref-type="fig"}*B*). Assuming a so-called park rate of approximately 10% of transferred cells, this approach was predicted to result in establishment of approximately 200 T~CM~ or 1000 T~EM~ in the lymphatics of recipient mice, equivalent to the number of endogenous Ag85B-specific cells we had observed 90 days after rBCG receipt (Figure [4](#JIU347F4){ref-type="fig"}). After resting for 2--3 days without Ag to favor a memory phenotype, recipient mice were challenged with aerosolized *M. tuberculosis*. Bacterial load was determined 21 days later. The donor memory T~EM~ and T~CM~/T~FH~ compartments were enumerated by flow cytometry in spleen and lung by means of CD90.1. Both populations survived and proliferated to a similar extent following *M. tuberculosis* challenge (Figure [7](#JIU347F7){ref-type="fig"}*C*). Transferred T~CM~/T~FH~ significantly decreased the *M. tuberculosis* burden, with the strongest effect in the lung and a trend toward reduced dissemination to other organs (Figure [7](#JIU347F7){ref-type="fig"}*D*). To determine whether protection was mediated by T~CM~ or T~FH~, we established an alternative double adoptive transfer system capable of inducing larger numbers of responding T cells than could be practically isolated from the polyclonal endogenous repertoire. We first transferred naive CD4^+^ T cells from T-cell receptor--transgenic P25 donor mice recognizing the same Ag85B epitope as the endogenous tetramer^+^ population. Naive recipients were then primed with rBCG to allow FACS separation of rare Ag-specific T~EM~, T~CM~, and T~FH~ for transfer into C57BL/6 mice prior to *M. tuberculosis* infection (Figure [7](#JIU347F7){ref-type="fig"}*E*). Intriguingly, transfer of purified P25 transgenic T~CM~ markedly protected against tuberculosis, in contrast to naive, T~EM~, or T~FH~ counterparts (Figure [7](#JIU347F7){ref-type="fig"}*F*). Thus, protection by rBCG primarily resided in the T~CM~ population in this adoptive transfer system. Figure 7.Adoptively transferred Ag85B-specific central memory CD4^+^ T cells (T~CM~) induced by rBCG protect against tuberculosis. *A*, Adoptive transfer strategy. Endogenous Ag85B-specific effector memory CD4^+^ T cells (T~EM~; CCR7^--^CXCR5^--^PD-1^--^; 8000 per recipient) and T~CM~/T follicular helper T cells (T~FH~; CCR7^+^CXCR5^+^PD-1^+^; 3000 per recipient) were FACS purified from rBCG vaccinated, congenic CD90.1^+^ mice and then transferred into naive C57BL/6 recipients. After 3 days of rest, recipients and controls were infected with low-dose aerosolized *Mycobacterium tuberculosis* and analyzed 21 days after infection. *B*, Cell-sorting strategy to separate CD4^+^Ag85B:I-Ab^+^ cells into T~EM~ and T~CM~/T~FH~ subsets as in panel *A*, and postsort expression of T~FH~ markers prior to transfer (right). *C*, Representative flow cytometry of CD90.1^+^ donor T~EM~ or T~CM~/T~FH~ after *M. tuberculosis* infection as in panel *A*, gated on total CD3^+^CD4^+^ cells in recipients of adoptive cell transfer. *D*, *M. tuberculosis* colony-forming units (CFU) after infection as in panel *A. E*, Second adoptive transfer strategy. A total of 1 × 10^5^ naive P25 Tg T cells were transferred into naive mice, which were then vaccinated with rBCG. Fourteen days later, donor cells were isolated by FACS and separated into T~EM~ (CCR7^--^CXCR5^--^PD-1^--^; 8000 per recipient), T~CM~ (CCR7^+^CXCR5^+^PD-1^--^; 3000 per recipient), and T~FH~ (CCR7^+^CXCR5^+^PD-1^+^; 2000 per recipient) for transfer into naive mice. After 3 days of rest, recipients of adoptive cell transfer and controls were infected with low-dose aerosolized *M. tuberculosis* and analyzed 28 days after infection. *F*, CFU after *M. tuberculosis* infection as in panel *E*. Data show mean values (± standard error of the mean) representative of 2 experiments (n = 3--6). \**P* \< .05, by the Mann--Whitney *U* test.

DISCUSSION {#s4}
==========

Recent interest has focused on T~CM~ as mediators of protection following vaccination with protein--adjuvant formulations as heterologous boosters. For example, LN-resident cells that were CD62L^+^CCR7^+^ and secreted interleukin 2 (IL-2) controlled *M. tuberculosis* upon transfer into immunodeficient mice \[[@JIU347C9]\]. Multifunctional T~CM~-like IL-2/TNF-α/IFN-γ^+^ cells have also been associated with protection following vaccination \[[@JIU347C31]--[@JIU347C34]\]. In humans, increasing evidence points to an association between *M. tuberculosis*--specific T~CM~ in peripheral blood and latent *M. tuberculosis* infection, rather than progression to active tuberculosis \[[@JIU347C35], [@JIU347C36]\]. Whether the ability to produce this polyfunctional cytokine profile upon restimulation is inherently protective in the lung or merely allows identification of T~CM~ with the capacity to generate a variety of different progeny during recall is the focus of ongoing studies. Our results demonstrate that rBCG induced higher absolute numbers and proportions of Ag-specific T~CM~ than BCG, with characteristic CXCR5^+^CCR7^+^ expression and an absence of effector transcription factors. Elevated T~CM~ numbers and proportions were evident at the peak of the response and were maintained after clearance of rBCG, suggesting that these cells arise during the T~H~ expansion but, unlike T~FH~, persist throughout the contraction phase to become T~CM~. Adoptive transfer of T~CM~ or cotransfer of T~CM~ and T~FH~ specific for a single mycobacterial Ag shared between rBCG and *M. tuberculosis*, Ag85B, sufficed for profound protection against pulmonary tuberculosis. T~FH~ alone were unable to significantly reproduce this effect, yet it is possible that these cells could inhibit *M. tuberculosis* if higher numbers were transferred. T~CM~ have been shown to generate a second wave of Ag-specific T~FH~ following reexposure to Ag, and this may also occur when BCG vaccination is followed by infection with *M. tuberculosis* \[[@JIU347C35]\]. Further transcriptome analysis of Ag-specific T~M~ may reveal further qualitative differences between memory subsets that were not observed in this study.

In mice and humans, circulating T~CM~ and T~FH~ both express CXCR5 and are frequently associated with enhanced Ab responses to infection \[[@JIU347C18], [@JIU347C37], [@JIU347C38]\]. Recent studies emphasized the importance of CXCR5 expression on mycobacteria-specific T cells for migration to organized lymphoid structures in the lung containing B cells in mouse, human, and nonhuman primate tuberculosis \[[@JIU347C39]--[@JIU347C41]\]. These structures and prevalent CXCR5-expressing T cells have been correlated with decreased lung pathology following vaccination and challenge with *M. tuberculosis*, rather than canonical Th1 or T~EM~ responses \[[@JIU347C42], [@JIU347C43]\]. It remains to be determined whether rBCG is associated with the development of ectopic lymphoid structures comprising T cells, B cells, and macrophages in the lung.

Intriguingly, enhanced production of mycobacterial Ag-specific Ab was a strong differentiating factor of the immune response to rBCG, compared with the response to BCG, in a phase 1 clinical trial \[[@JIU347C16]\]. We identified a profound increase in T~FH~ and associated Ab production following rBCG receipt, compared with BCG receipt, as well as formation of germinal centers in draining LNs (data not shown). Secreted protein Ag are preferred targets of both B and T cells in tuberculosis \[[@JIU347C35]\]. Therefore, increased B-cell activation following rBCG receipt may facilitate collaboration for cognate Ag presentation. Indeed, polyfunctional T~CM~ and T~FH~ both uniquely depend on strong T-cell receptor signals for their development \[[@JIU347C44]--[@JIU347C46]\]. Alternatively, complexes derived from Ab and mycobacterial Ag captured by follicular dendritic cells in long-lasting germinal centers could favor differentiation of protective T~CM~ and T~FH~. In murine *Listeria monocytogenes* and lymphocytic choriomeningitis virus infection, Ag presentation by B cells is directly correlated with increased differentiation of monoclonal transgenic T cells into T~CM~ and T~FH~ phenotypes \[[@JIU347C18], [@JIU347C47]\]. More recently, marked T~FH~ responses were found to correlate with development of broadly neutralizing Ab to HIV or autoantibodies in humans \[[@JIU347C37], [@JIU347C48]\].

In conclusion, our findings reveal that receipt of rBCG induces a superior Ag-specific T~CM~ response over BCG, which contributes to protection against tuberculosis. Novel tuberculosis prime or boost strategies should target the expansion of this T~CM~ subset, with the aim of improving long-lasting protection. Moreover, our results emphasize the potential usefulness of the rBCG expressing heterologous Ag from pathogens that are more susceptible to neutralizing Ab, owing to its safety and targeted activation of sustained T~FH~ and B-cell immunity.
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